Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-04-23
1995-08-01
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544357, A61K 31495
Patent
active
054380570
ABSTRACT:
A compound of formula (II): ##STR1## in which R.sub.1 and R.sub.2 together form a methylene or ethylene bridging group and R.sub.3 is a hydrogen, an acyclic aliphatic hydrocarbon group having a maximum of six carbon atoms or a group CH.sub.2 R.sub.4 in which R.sub.4 is a C.sub.1-5 alkyl group substituted by a hydroxy group or by a C.sub.1-6 alkoxy group, or a salt thereof formed with a physiologically acceptable inorganic or organic acid, are of value for use in therapy, particularly as cardioprotective agents.
REFERENCES:
patent: 3164580 (1965-01-01), Matson
patent: 3196153 (1965-07-01), Dazzi
patent: 3941790 (1976-03-01), Creighton
patent: 4051137 (1977-09-01), Ramey et al.
patent: 4275063 (1981-06-01), Creighton
patent: 4404381 (1983-09-01), Woo
patent: 4432907 (1984-02-01), Wieder et al.
patent: 4755619 (1988-07-01), Creighton et al.
patent: 4902714 (1990-02-01), Creighton et al.
patent: 5149710 (1992-09-01), Creighton et al.
patent: 5162372 (1992-11-01), Creighton et al.
patent: 5278187 (1994-01-01), Creighton et al.
E. H. Herman et al. "Comparison of the Protective . . ." Res Comm in Chem Pathology & Pharmaco.ilogy, vol. 48 No. 1, Apr. 1985, pp. 39-55.
V. J. Ferrans et al. "Pretreatment with ICRF-187 . . . " Dev Oncolog 1988, vol. 53, pp. 56-63.
A. N. El-Hage et al. "Examination of the Protective . . . " Toxicology, 18 (1988) pp. 295-303.
A. N. El-Hage et al. "Reduction in the Diabetogenic . . . " Res Comm in Chem Pathology & Pharmacology, vol. 33, No. 3, Sep. 1981, pp. 509-523.
M. J. Willes et al. "Lead poisoning--a potentially . . . " Pizen. Lek. Sborn. Suppl. 1985, pp. 113-115.
Z. Huang et al. "Metal binding by pharmaceuticals . . . " Agents and Actions 1984, pp. 536-542.
P. M. May et al. "Metal binding by pharmaceuticals . . . " Agents and Actions, vol. 15, 3/4 (1984), pp. 448-453.
U. Witting et al. "Lead Elimination by ICRF 158 . . . " Int. Arch. Env. Occup. Health (1981), pp. 89-98.
Z. Huang et al. "Metal binding properties of two homologues . . . " Inorganica Chimica Acta 1985, pp. L29-L32.
E. H. Herman et al. "Comparison of the effectiveness of (.+-.) . . . " Cancer Research, 45, Jan. 1985, pp. 276-281.
E. H. Herman et al. "Reduction of chronic doxorubicin cardiotoxicity . . . " Cancer Research 41, Sep. 1981, pp. 3436-3440.
D. D. Von Hoff et al. "Phase 1 study of ICRF-187 using . . . " Cancer Treatment Reports, vol. 65 No. 3-4, Mar./Apr. 1981, pp. 249-252.
E. H. Herman et al. "Reduction of chronic daunorubicin . . . " Res. Comm. in Chem Pathology & Pharmacology, vol. 31, No. 1, Jan. 1981, pp. 85-97.
E. H. Herman et al. "Influence of Vitamin E and ICRF-187 . . . "Laboratory Investigation, vol. 49 No. 1 (1983), pp. 69-77.
E. Herman et al. "Reduction of Daunorubicin lethality . . . " Cancer Treatment Reports, vol. 63 No. 1 (Jan. 1979), pp. 89-92.
Brian B. Hasinoff. "The interaction of the cardioprotective . . . " Agents and Actions, vol. 26 No. 3/4 (1989), pp. 378-385.
A. M. Creighton et al. "Antitumor activity in a series of . . . " Nature, vol. 222, Apr. 26, 1969, pp. 384-385.
A. M. Creighton. "Bisdiketopiperazines: A new class of antitumor . . . " Prog. in Antimicrobial & Anticancer chemotherapy, 1970, pp. 167-169.
J. C. Cai et al. "MST-16 and ZSB14 21, new antitumor agents" Poster, 14th Intl Congress of Chem. Jun. 23-28, 1985, pp. 1-9.
A. M. Creighton et al. "Ester Amide derivatives of ethylenediamine . . . " Recent Advances in Chemotherapy, Proc. of 14thInlt Cong of Chem. 1985, pp. 481-482.
U. Witting et al. "Der Enflu . . . " International Arch. Occup. Env. Health, 1979, pp. 365-373.
Z. Tanmu et al. "Pharmacological studies on bimolane . . . " Acta Pharmaceutica Sinica, vol. XV No. 10 (Oct. 1980), pp. 582.
S. A. Mortensen et al. "Clinical & non-invasive assessment of . . . " Int. J. Clin Pharm Res VI (2) (1986), pp. 137-150.
J. L. Speyer et al. "Protective effect of the . . . "New England Journal of Medicine, vol. 319 No. 12, pp. 745-752 (1988).
Chemical Abstarct #124811c "Acid Amides" vol. 82 (1975) p. 513. R. P. Houghton Synthesis of Bis . . . J Chem Soc Perkin Trans I 1982, p. 2693.
E. H. Herman et al. "Pretreatment with ICRF-187 . . . " Cancer Chemother Pharmacol (1986) 16:, pp. 102-106.
E. H. Herman et al. "Reduction of chronic . . . "Cancer Chemother. Pharmacol. 1986, pp. 277-281.
A. M. Creighton et al. "The effect of bisdioxopiperazines . . . " Proceedings of the Biochemical Society, p. 58 (1992).
D. T. Witiak et al. "Syntheses and .sup.1 H NMR Conformational . . . "J. Org. Chem. 1991, 56, pp. 5408-5417.
D. T. Witiak et al. "Stereoselective effects of cis- and trans-. . . "Jour of Medicinal Chem vol. 21 No. 12 (1978), pp. 1195-1197.
D. T. Witiak et al. "Study of trans-cyclopropybis . . . " Journal of Medicinal Chemistry, 1977, vol. 20 No. 5, pp. 630-635.
U. Witting et al. "Lead elimation by ICRF-158 in rats . . . " Int Arch Occup Environ Health 1979, 87-90.
Chemical Abstracts #197550d, vol. 93 No. 21 Nov. 24 (Columbus, Ohio, USA).
Chemical Abstracts #136564m, vol. 88 No. 19 May 8, 1978 (Columbus, Ohio, USA).
Zwilling, B. S. et al "Effect of stereoisomer . . . "Brit. J. Cancer, vol. 44, No. 4 (1981), pp. 578-583.
Herman, E. H. et al "Biological properties of ICRF-159 . . . "Advances in Pharmacology & Chemo., vol 19. (1982), pp. 254-257, 278-286.
Woodman, R. J. et al "Enhancement of the effectiveness . . . "Cancer Chemotherapy Reports, vol. 59 No. 4 part 1 Jul./Aug. 1975, pp. 689-695.
Hempeol, A. et al "Stereochemistry of conformationally . . . " Journal of the Chemical Society, vol. 104 No. 12 (1982), pp. 3456-3458.
E. H. Herman et al "Comparison of the protective . . . " Research Comm. in Chemical Pathology & Pharmacology, vol. 48 No. 1 (Apr. 1985), pp. 39-55.
T. K. Yeung et al. "ICRF 197: a new agent for protecting against . . . " Cellualr Pharmacology Laboratory, ICRF, London WC2A 3PX & CRC Normal Tissue Radiobiology Research Group, Oxford, OX3 7LJ, pp. 3-8.
British Technology Group Limited
Reamer James H.
LandOfFree
Pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-733947